NASDAQ:BLCM Bellicum Pharmaceuticals (BLCM) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free BLCM Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.07▼$0.0950-Day Range$0.07▼$0.1052-Week Range$0.06▼$1.31Volume6,000 shsAverage Volume22,874 shsMarket Capitalization$727,056.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisEarningsOwnershipSocial MediaStock AnalysisEarningsOwnershipSocial Media Get Bellicum Pharmaceuticals alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Bellicum Pharmaceuticals Stock (NASDAQ:BLCM)Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.Read More Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. BLCM Stock News HeadlinesApril 16, 2024 | americanbankingnews.comBellicum Pharmaceuticals (NASDAQ:BLCM) Share Price Crosses Above 50-Day Moving Average of $0.08April 16, 2024 | americanbankingnews.comBellicum Pharmaceuticals (NASDAQ:BLCM) Receives New Coverage from Analysts at StockNews.comApril 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.February 22, 2024 | msn.comBellicum sells assets to MD Anderson, moves towards liquidationJanuary 25, 2024 | msn.comBellicum Pharmaceuticals Issues Super-Voting Share PrivatelyDecember 23, 2023 | morningstar.comBellicum Pharmaceuticals Inc BLCMDecember 8, 2023 | benzinga.comBellicum Pharmaceuticals Stock (OTC:BLCM), Short Interest ReportOctober 27, 2023 | finance.yahoo.comFutura Medical plc (FAMDF)April 25, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.July 13, 2023 | finance.yahoo.comBLCM - Bellicum Pharmaceuticals, Inc.June 3, 2023 | fool.comBellicum Pharmaceuticals (NASDAQ: BLCM)May 8, 2023 | investorplace.comWhy Is Bellicum Pharmaceuticals (BLCM) Stock Up 75% Today?April 18, 2023 | msn.comWhy Digital Brands Group Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving PremarketApril 18, 2023 | benzinga.comShort Volatility Alert: Bellicum PharmaMarch 15, 2023 | msn.comBLCM Plummets on Stopping Trials of BPX-601 and BPX-603March 15, 2023 | msn.comWhy Bellicum Pharmaceuticals (BLCM) Stock Is Down 48%March 14, 2023 | finance.yahoo.comBellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic AlternativesFebruary 24, 2023 | finance.yahoo.comWhy Bellicum Pharmaceuticals Stock Is Plunging TodayFebruary 16, 2023 | finance.yahoo.comBellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers SymposiumJanuary 31, 2023 | finance.yahoo.comCORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 19, 2023 | finance.yahoo.comBellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers SymposiumNovember 13, 2022 | finanznachrichten.deBellicum Pharmaceuticals, Inc.: Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational UpdateNovember 10, 2022 | finance.yahoo.comBellicum Reports Third Quarter 2022 Financial Results and Provides Operational UpdateOctober 4, 2022 | finance.yahoo.comBellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the MesaSeptember 15, 2022 | seekingalpha.comBLCM Bellicum Pharmaceuticals, Inc.September 1, 2022 | finance.yahoo.comBellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 25, 2022 | finance.yahoo.comBellicum Pharmaceuticals (BLCM) Could Find Support Soon, Here's Why You Should Buy the Stock NowSee More Headlines Receive BLCM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2021Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:BLCM CUSIPN/A CIK1358403 Webwww.bellicum.com Phone(281) 454-3424FaxN/AEmployees13Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,970,000.00 Net MarginsN/A Pretax Margin-1,492.40% Return on EquityN/A Return on Assets-157.93% Debt Debt-to-Equity RatioN/A Current Ratio3.04 Quick Ratio3.04 Sales & Book Value Annual Sales$1.50 million Price / Sales0.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book0.33Miscellaneous Outstanding Shares9,720,000Free Float8,716,000Market Cap$727,056.00 OptionableNot Optionable Beta1.39 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. David M. Maggio (Age 64)Chief Executive Officer Mr. Joseph Senesac (Age 54)Senior Vice President of Technical Operations & Quality Dr. Alan K. Smith Ph.D. (Age 66)Chief Scientific Officer Comp: $536.43kKey Competitors9 Meters BiopharmaNASDAQ:NMTREiger BioPharmaceuticalsNASDAQ:EIGRBellerophon TherapeuticsNASDAQ:BLPHSientraNASDAQ:SIENQEvelo BiosciencesNASDAQ:EVLOView All Competitors BLCM Stock Analysis - Frequently Asked Questions How were Bellicum Pharmaceuticals' earnings last quarter? Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) announced its quarterly earnings data on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.37) by $1.15. The biopharmaceutical company had revenue of $0.70 million for the quarter. When did Bellicum Pharmaceuticals' stock split? Shares of Bellicum Pharmaceuticals reverse split on the morning of Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Bellicum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO). When did Bellicum Pharmaceuticals IPO? Bellicum Pharmaceuticals (BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager. This page (NASDAQ:BLCM) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThese AI trades triggered this morning (545% return)Prosper Trading Academytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressFed launches fourth dollar overhaulStansberry ResearchThe AI stock to buy right nowStockEarningsExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellicum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
